Remicade has been linked to making first vaccine doses less effective.
A recent study published on medRxiv on March 29 has shown that frequent infusions of infliximab (Remicade) have been linked to making first vaccine doses in both Pfizer and AstraZeneca less effective.
The study’s researchers have discovered that patients who were receiving regular infliximab injections as an antibody treatment for several chronic inflammatory illnesses did not produce enough antibodies to offer protection against COVID-19, after the first vaccine dose.
Remicade is usually used for treating several autoimmune disorders, such as ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, rheumatoid arthritis, ulcerative colitis, and plaque psoriasis.
If you’re currently on treatment with infliximab, it would be advised to consult with your doctor before the COVID-19 vaccination to find out what’s the best option for you.
Make sure to also check: This Covid Guideline Is About To Change, According To The CDC.
Leave a Reply